Huons leads the way in the health supplement market

Home > National >

print dictionary print

Huons leads the way in the health supplement market

Prostate Quisqualis is a multipurpose health supplement that assists men’s prostate health. [HUONS]

Prostate Quisqualis is a multipurpose health supplement that assists men’s prostate health. [HUONS]

 
Huons is paving its way in the health supplement market with Prostate Quisqualis and Elruby Menolacto Probiotics.
 
Huons hopes to expand into men’s prostate health with Prostate Quisqualis, an innovative health product which is comprised of plum blossom, orchid, bamboo, and chrysanthemum.  
 
The significant properties of these ingredients have been acknowledged by the Ministry of Food and Drug Safety. Otherwise known as the four noble plants of Asia, a powder extracted from these ingredients has shown high performance in moderating symptoms related to prostate health such as nocturia and pollakisuria.
 
Numerous experiments have displayed positive outcomes in the International Prostate Symptom Score (IPSS), proving the product’s effectiveness in successfully reducing prostate volume and genes that accelerate its growth rate.  
 
The product also constitutes Octacosanol, used to improve stamina, as well as zinc. The three main compositions enable well-balanced assistance for overall health care. Tablets are individually enclosed within separate packages, eliminating any negative impact from humidity or oxidation.
 
Huons recognizes the fact that prostate-related diseases are major menopausal symptoms and encourages men to efficiently prevent such conditions by efficiently taking care of themselves on a daily basis. It is expected that the product will become a solution for middle-aged men who overlook medical treatment of prostate health.
 
“Despite the fact that a number of middle-aged men suffer from prostate-related illnesses, few related treatments or health supplements exist,” said a Huons official. “Prostate Quisqualis itself is Huons’s accumulated knowledge and research on about 200 natural ingredients that assure effective and safe application on prostate symptom,” he added.
 
Huons has succeeded in commercializing health supplement Elruby Menolacto Probiotics, a representative product for soothing menopausal symptoms.  
 
Released in April, 2020, Elruby Menolacto Probiotics has recorded 78.7 billion ($61.6 million) in sales within two years and three months. According to a Korean research institute Embrain, the product ranked first in purchase rate, recognition and preference sectors for menopausal health supplements in June last year.  
 
It is suggested that the popularity of probiotics and the innovative attempt at health supplements professionally designed for people struggling with menopausal problems triggered the needs of customers. The product’s model, Park Mi-sun, who had reported personal tales of suffering from menopausal problems, is also considered an appealing factor. By Park using the slogan, “Don’t endure menopause,” women could relate to the philosophy and values of the supplement.  
 
This year Elruby Menolacto Probiotics is going to concentrate more on expanding recognition among customers. It is now considered a mega-brand. Via repetitive usage of the terms, menopause and lactobacillus, which correspondingly refer to menopausal symptoms and treatment, the company has coined the slogan “representative health supplement for the middle-aged”.
 
The key ingredient of Elruby Menolacto Probiotics is lactobacillus acidophilus YT1, a lactobacillus acknowledged by the Ministry of Food and Drug Safety.  
 
Elruby Menolacto Probiotics has succeeded in curing a range of menopausal symptoms including colpoxerosis and hypersensitivity. It has also received positive feedback from the Menopause-specific Quality of Life Questionnaire.
 

BY PARK YE-EUN [park.yeeun@joongang.co.kr]
Log in to Twitter or Facebook account to connect
with the Korea JoongAng Daily
help-image Social comment?
s
lock icon

To write comments, please log in to one of the accounts.

Standards Board Policy (0/250자)